Systems biology of cyanobacterial secondary metabolite production and its role in drug discovery
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cyanobacteria continue to be an important source of compounds that show unprecedented biological activities of pharmaceutical interest. Cyanobacterial metabolites show an interesting and exciting range of biological activities ranging from antimicrobial and immunosuppressant to anticancer and anti-HIV. OBJECTIVE: This review explores the possibilities of applying systems biology approaches for harnessing these compounds as drug leads, primarily produced through large multimodular non-ribosomal peptide synthetase (NRPS), polyketide synthase (PKS) and mixed NRPS-PKS enzymatic systems. METHODS: A brief survey of the strategies for in silico analysis for drug target identification using genomic and high-throughput proteomics data, virtual screening and receptor-ligand docking based approaches are also discussed. CONCLUSION: We conclude with an outlook on how the field will evolve, especially in partnership with the new engineering-based, more endpoint exploitative paradigm of synthetic biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400129-mcp200 · Cited by 4,401 · cited 2×
“These limitations were surpassed by the isobaric tagging for relative and absolute quantification (iTRAQ) approach [140] .”
MethodSystems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265 · cited 1×
“Systems biology can be defined as the study of the relationship between different interacting components of a living system – such as cells, tissues and metabolic pathways – and an organism, and the integration of these studies to gain an insight into how the living systems work [38,39] .”
BackgroundCorrelation between Protein and mRNA Abundance in Yeast
Gygi, S. P., Rochon, Y., Franza, B. R., & Aebersold, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1720 · Cited by 3,819
Metabolomics—the link between genotypes and phenotypes
Fiehn, O. (2002) · Plant Molecular Biology · doi:10.1023/a:1013713905833 · Cited by 3,445 · cited 1×
“[150] when they developed a G protein-coupled receptor microarray that included the co-immobilisation of lipid molecules and the probe receptors of interest using conventional robotic printing technologies.”
MethodProduction of the antimalarial drug precursor artemisinic acid in engineered yeast
Ro, D.-K., Paradise, E. M., Ouellet, M., Fisher, K. J., Newman, K. L., Ndungu, J. M., Ho, K. A., Eachus, R. A., Ham, T. S., Kirby, J., et al. (2006) · Nature · doi:10.1038/nature04640 · Cited by 2,805 · cited 1×
“coli [207] for potent antibiotic erythromycin C production, and the second is the installation of a terpenoid production pathway in E.”
BackgroundSystematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Marine cyanobacteria—a prolific source of natural products
Burja, A. M., Banaigs, B., Abou-Mansour, E., Grant Burgess, J., & Wright, P. C. (2001) · Tetrahedron · doi:10.1016/s0040-4020(01)00931-0 · Cited by 841
Self-citationMarine natural products as anticancer drugs
Simmons, T. L., Andrianasolo, E., McPhail, K., Flatt, P., & Gerwick, W. H. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.333.4.2 · Cited by 597 · cited 2×
“Several marine invertebrates such as sponges and ascidians are well-known for producing biologically active compounds, and many of them are undergoing clinical trials [18,24] .”
BackgroundSchmidt, E. W., Nelson, J. T., Rasko, D. A., Sudek, S., Eisen, J. A., Haygood, M. G., & Ravel, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501424102 · Cited by 567 · cited 2×
“Prochloron didemni Cyclic peptide Cytotoxic, biological activity against multi-drug resistant UO-31 renal cell lines Patellamide A, B, C and D [27]”
BackgroundBioactive natural products from marine cyanobacteria for drug discovery
Tan, L. T. (2007) · Phytochemistry · doi:10.1016/j.phytochem.2007.01.012 · Cited by 534 · cited 2×
“It is well known that cyanobacteria and other prokaryotes can produce biologically active compounds through NRPS, PKS and mixed NRPS–PKS pathways [21,80-87] .”
Background
Cited by
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
Li, J. W.-H., & Vederas, J. C. (2009) · Science · doi:10.1126/science.1168243 · Cited by 2,052
Ecology of Cyanobacteria II: Their Diversity in Space and Time
(2012) · doi:10.1007/978-94-007-3855-3 · Cited by 1,078
Biotechnological and industrial significance of cyanobacterial secondary metabolites
Rastogi, R. P., & Sinha, R. P. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.04.009 · Cited by 357
Cyanobacteria: Review of Current Potentials and Applications.
Zahra, Z., Choo, D. H., Lee, H., & Parveen, A. (2020) · Environments · doi:10.3390/environments7020013 · Cited by 228
Pharmaceutical applications of cyanobacteria—A review
Vijayakumar, S., & Menakha, M. (2015) · Journal of Acute Medicine · doi:10.1016/j.jacme.2015.02.004 · Cited by 205
Sustainability and cyanobacteria (blue-green algae): facts and challenges
Sharma, N. K., Tiwari, S. P., Tripathi, K., & Rai, A. K. (2011) · Journal of Applied Phycology · doi:10.1007/s10811-010-9626-3 · Cited by 178
“In recent times, their ability to produce structurally novel and biologically active natural products has been recognised (Ordog et al. 2004; Gademan and Portman 2008; Sielaff et al. 2008; Wase and Wright 2008; Rosenberg et al. 2008; Tan 2010).”
BackgroundVersatile Applications of Cyanobacteria in Biotechnology
Żymańczyk-Duda, E., Samson, S. O., Brzezińska-Rodak, M., & Klimek-Ochab, M. (2022) · Microorganisms · doi:10.3390/microorganisms10122318 · Cited by 64
Metadata
- Authors
- Wase, N. V., & Wright, P. C.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2008-07-16
- Volume
- 3
- Issue
- 8
- Pages
- 903-929
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2135861142
- Cited by
- 58
- References
- 16
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.